Gilead plans to go straight to Phase III studies for once-yearly lenacapavir, while GSK and Viiv will push forward with their ...

Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir ...

Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...

Germany's financial markets watchdog is looking at whether Bayer fairly disclosed plans for shareholder approval of a capital ...

Gilead (GILD) stock in focus as its HIV anti-viral lenacapavir shows promise in HIV prevention with once-yearly PrEP ...

The drug, which works by blocking HIV from entering and multiplying in human cells, remained in the body for at least 56 ...

Sciences presented the first data from its ongoing Phase 1 study investigating two novel, once-yearly formulations of ...

Bernstein analyst Courtney Breen maintained a Buy rating on Gilead Sciences (GILD – Research Report) yesterday and set a price target of ...

Academy Award winning filmmaker Martin Scorsese ( Taxi Driver , Goodfellas , Killers of the Flower Moon ) has signed on to ...

A Lancet study shows promising results for an annual HIV prevention injection, lenacapavir. In Stage 1 trials, 40 HIV-negative participants had no significant side effects ...

Martin Scorsese and Apple Original Films are reportedly adapting Marilynne Robinson's Gilead novels with Leonardo DiCaprio ...

Checkpoint inhibitors are drugs that harness the immune system to destroy cancer cells. Let us review what’s been going on in the field.